1.
J Coll Physicians Surg Pak
; 30(6): 78, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: covidwho-690621
Asunto(s)
Betacoronavirus/efectos de los fármacos , Cloroquina/toxicidad , Cloroquina/uso terapéutico , Infecciones por Coronavirus/tratamiento farmacológico , Hidroxicloroquina/toxicidad , Hidroxicloroquina/uso terapéutico , Neumonía Viral/tratamiento farmacológico , Betacoronavirus/aislamiento & purificación , COVID-19 , Cloroquina/administración & dosificación , Infecciones por Coronavirus/complicaciones , Infecciones por Coronavirus/epidemiología , Humanos , Hidroxicloroquina/administración & dosificación , Pandemias , Neumonía Viral/complicaciones , Neumonía Viral/epidemiología , SARS-CoV-2 , Tratamiento Farmacológico de COVID-19
2.
Disaster Med Public Health Prep
; 14(4): e9-e10, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: covidwho-636862
RESUMEN
The incidence of extensively drug-resistant tuberculosis (XDR-TB) has been rising consistently in Pakistan, and the country is likely to experience another surge of cases in the midst of the COVID-19 crisis. It is imperative to consider how the rising proportion of XDR-TB is best tackled during the pandemic; this includes finding a solution to the problem of non-adherence at the level of community-based healthcare, the utility and practicality of simultaneous testing for COVID-19 and TB, and reconciliation of the World Health Organization's recommendation of home-based treatment with the need for frequent monitoring of anti-tubercular therapy in XDR-TB. Operational research is needed expeditiously to bypass these limitations.